Dating chat venn
Cash and cash equivalents remained strong at €3.4m at 31 December 2016 and we are forecasting for FY 2017 cash and cash equivalents of £3.6m.With that said, a HY 2017 cash of €2.9m puts the Company in a strong cash position."rivaldo: FYI here's Hybridan's summary and new forecasts from 2 weeks ago: "Continuing growth not recognised in current price. €m 2015A 2016A 2017E 2018E Total Income 11.64 18.24 19.29 21.22 PBT* 0.72 0.27 1.27 1.57 Update 31 March 2017 Venn’s full year results last week highlighted some of the growing pains associated with high growth companies and bedding down significant acquisitions.There are currently 71,395,148 shares in issue and the average daily traded volume is 0 shares.The market capitalisation of Venn Life Sciences Holdings Plc is £4,890,567.64.yump: "continue to look at PLC costs" Does that mean take the company private at or near the nadir, issue some more shares to certain people at a pittance and then refloat under a different name, if business picks up at a multiple of that share price.That will be the case even if VENN fails to achieve Hybridan's forecast £1.27m adjusted PBT, which I'm not sure they will.
The last closing price for Venn Life Sciences was 6.85p.
They're paying €5.7m for a business with €4.7m of annual revenues and €0.34m EBITDA.
VENN are forecast to make €18.5m revenues this year, with €0.9m EBITDA.
We would expect that Venn continues to evaluate complementary acquisition targets which could at least in part be funded from its current balance sheet depending on size.
The Company is well positioned to accelerate its win rate particularly with Biotechnology companies where its offering of a full lifecycle service combined with a customer-centric flexible approach sets it apart from the competition.